Phosphopeptide pTyr-Glu-Glu-Ile (pYEEI) has been introduced as an optimal Src SH2 domain ligand. Peptides, Ac-K(IDA)pYEEIEK(IDA) (1), Ac-KpYEEIEK (2), Ac-K(IDA)pYEEIEK (3), and Ac-KpYEEIEK(IDA) (4), containing 0-2 iminodiacetate (IDA) groups at the N-and C-terminal lysine residues were synthesized and evaluated as the Src SH2 domain binding ligands. Fluorescence polarization assays showed that peptide 1 had a higher binding affinity (K d = 0.6 µM) to the Src SH2 domain when compared with Ac-pYEEI (K d = 1.7 µM), an optimal Src SH2 domain ligand, and peptides 2−4 (K d = 2.9-52.7 µM). The binding affinity of peptide 1 to the SH2 domain was reduced by more than two fold (K d = 1.6 µM) upon addition of Ni 2+ (300 µM), possibly due to modest structural effect of Ni 2+ on the protein as shown by circular dichroism experimental results. The binding affinity of 1 was restored in the presence of EDTA (300 µM) (K d = 0.79 µM). These studies suggest that peptides containing IDA groups may be used for designing novel SH2 domain binding ligands.
Keywordsphosphopeptides; metal chelation; iminodiacetate group; SH2 domain; UV titration; fluorescence polarization; circular dichroism
IntroductionSrc, one of the first studied non-receptor tyrosine kinases, has been implicated in the genesis and progression of multiple types of human diseases including colon, breast, lung cancers, osteoporosis, and inflammation-mediated bone loss [1,2]. Src tyrosine kinase contains three major domains, in the order from N-to C-terminal, two regulatory Src homology (SH) domains (SH3 and SH2 domains), and a kinase domain. The Src SH2 domain is a relatively small protein module of approximately 100 amino acids and has extraordinary ability to recognize specifically sequences containing phosphotyrosine residue (pTyr), thereby facilitating phosphorylation-dependent protein-protein interactions that result in signal transduction process [3]. Short peptide inhibitors capable of disrupting these interactions have been designed as useful tools in the mechanistic studies of the Src SH2 domain interactions and as potential
NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript inhibitors for further pharmaceutical development [4−8]. The Src SH2 domain preferentially binds peptides with the sequence pTyr-Glu-Glu-Ile (pYEEI) with high affinity [9].The use of conformationally constrained peptides has been shown to be an effective strategy in developing therapeutic peptidic and peptidomimetic agents [10,11]. Constrained peptides are usually more stable towards enzymatic degradations. We previously reported the synthesis and evaluation of a series of covalently bonded conformationally constrained peptide analogues based on the optimal sequence pYEEI as inhibitors of the Src SH2 domain [8]. A number of conformationally constrained peptides showed at least 100-fold fold increase in the binding affinities to the Src SH2 domain relative to pYEEI and the corresponding linear peptides, respectively. The enhancement in binding affinities was a...